Member Exclusive
INTERVIEW
Latest news & views, Spotlight on gene therapy, Spotlight on immunotherapy, Spotlight on commercialization and translation, Spotlight on cell therapy regulation, Cell therapy, Ethics & policy, Industry developments, Manufacturing & scale-up
Overcoming the obstacles to a commercially successful cell or gene therapy: an interview with Dr Nafees Malik
In this interview, one of the world’s leading authorities on the commercialization of cell and gene therapies, Dr Nafees Malik, founder and CEO of Asklepian Consulting, explains the keys to successfully developing and commercializing a cell or gene product.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Sign up today!
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>
1 Comments
I am always frustrated by the question: autologous vs allogeneic. There is plenty of room for both models in the future of medicine. Allogeneic cell therapy is easy to love from a business model perspective but it faces struggles when proving efficacy. The article seems to ignore all the investment and business enthusiasm for cell-based immunotherapy which is almost all based on use of autologous cells.